Status:

COMPLETED

The Study of the BX Velocity Stent in the Treatment of De Novo Artery Lesions.

Lead Sponsor:

Cordis US Corp.

Conditions:

Coronary Artery Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The main objective of this study is to assess the safety and effectiveness of the sirolimus-coated Bx VELOCITY™ stent in maintaining minimum lumen diameter in de novo native coronary artery lesions as...

Detailed Description

This is a multicenter ,prospective, randomized double blind study. This study has a 2-arm design assessing the safety and effectiveness of the sirolimus-coated Bx VELOCITY™ stent to the uncoated Bx VE...

Eligibility Criteria

Inclusion

  • Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II) OR patients with documented silent ischemia;
  • Single treatment of de novo lesion in a major coronary artery in patients with single or multi-vessel disease; patients with multiple lesions can be included only if the other lesions do not require treatment;
  • Target vessel diameter at the lesion site is \>=2.50mm and \<=3.0mm in diameter (visual estimate);
  • Target lesion is \>=15mm and \<=32mm in length (visual estimate);
  • Target lesion stenosis is \>50% and \<100% (visual estimate);

Exclusion

  • Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK \>2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remains above normal at the time of treatment;
  • Has unstable angina classified as Braunwald III B or C and A I-II-III, or is having a peri infarction;
  • Unprotected left main coronary disease with \>=50% stenosis;
  • Significant (\>50%) stenoses proximal or distal to the target lesion that might require revascularization or impede runoff;
  • Have an ostial target lesion;
  • Angiographic evidence of thrombus within target lesion;
  • Heavily calcified lesion which cannot be successfully predilated;
  • Documented left ventricular ejection fraction \<=25%.

Key Trial Info

Start Date :

March 1 2001

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2008

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00381420

Start Date

March 1 2001

End Date

June 1 2008

Last Update

October 31 2008

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.